Apogee Therapeutics, Inc.

APGE

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001104659-26-023651
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026
Reporting Owners: Henderson Jane (CFO)

Summary

Type

Sell

Net shares

-2,000

% of shares

-1.09%

Amount (USD)

$140,431

Insider confidence score

46.3 out of 100

Positive

  • Under Rule 10b5-1 trading plan

Negative

  • Moderate scheduled sell (<2% of shares)
  • Significant sell amount ($50K+)

Stock transactions

Transaction 1

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-300.0

Price per Share

$68.27

Amount (USD)

$20,481.00

Acquired/Disposed

Disposed

Shares Owned Before

183,371.0

Shares Owned After

183,071.0

Transaction 2

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-300.0

Price per Share

$69.43

Amount (USD)

$20,829.00

Acquired/Disposed

Disposed

Shares Owned Before

183,071.0

Shares Owned After

182,771.0

Transaction 3

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-994.0

Price per Share

$70.45

Amount (USD)

$70,027.30

Acquired/Disposed

Disposed

Shares Owned Before

182,771.0

Shares Owned After

181,777.0

Transaction 4

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-406.0

Price per Share

$71.66

Amount (USD)

$29,093.96

Acquired/Disposed

Disposed

Shares Owned Before

181,777.0

Shares Owned After

181,371.0

Filing's footnotes

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.77 to $68.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the &quot;SEC&quot;), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.91 to $69.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.03 to $70.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.04 to $71.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

ℹ️ Filed under Rule 10b5-1 trading plan

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.